Table 1.
Finite element strength in the different loading modes (anterior bending, axial compression, axial torsion) and normalized axial compression strength for the teriparatide and risedronate treatment groups
| Variable | Time (months) | Teriparatide | Risedronate | p value a | ||
|---|---|---|---|---|---|---|
| n | Mean (SD) | n | Mean (SD) | |||
| Finite element strength | ||||||
| Anterior bending (kN mm) | Baseline | 36 | 94.7 (41.8) | 36 | 96.2 (42.3) | – |
| 6 | 25 | 121.3 (49.9) | 32 | 113.5 (46.0) | 0.661 | |
| 18 | 29 | 140.2 (58.8)b | 31 | 112.8 (40.8) | 0.012 | |
| Axial compression (kN) | Baseline | 36 | 5.07 (2.33) | 37 | 4.90 (2.28) | – |
| 6 | 25 | 6.21 (2.87) | 33 | 5.81 (2.23) | 0.547 | |
| 18 | 31 | 7.08 (3.48)b | 31 | 5.95 (2.2) | 0.015 | |
| Axial torsion (kN mm) | Baseline | 36 | 48.4 (22.1) | 37 | 48.6 (21.2) | – |
| 6 | 25 | 62.4 (26.3) | 33 | 57.9 (20.9) | 0.548 | |
| 18 | 31 | 71.0 (31.8)b | 31 | 58.2 (19.2) | 0.005 | |
| Normalized axial compression strength (N/mm2) | ||||||
| Baseline | 36 | 4.50 (2.20) | 37 | 4.41 (2.16) | – | |
| 6 | 25 | 5.32 (2.71) | 33 | 5.25 (2.18) | 0.677 | |
| 18 | 31 | 6.13 (3.29)b | 31 | 5.38 (2.08) | 0.021 | |
a p value for between group comparison
bChange from baseline within groups (p < 0.05) from a mixed model repeated-measures analysis of changes from baseline including fixed effects for treatment, visit and the interaction between treatment and visit, and random effects for patients nested within treatment, plus the following covariates: age, baseline PINP, fracture <12 months before study, duration of prior bisphosphonate use, screening GC dose, and cumulative GC dose prior to and during study. MMRM sample sizes for changes from baseline to 6 months (n = 23), and to 18 months (n = 28) for Teriparatide; and baseline to 6 months (n = 28), and to 18 months (n = 28) for Risedronate